Abstract
Purpose: To perform a randomized trial comparing 70 and 80 Gy radiotherapy for prostate cancer. Patients and Methods: A total of 306 patients with localized prostate cancer were randomized. No androgen deprivation was allowed. The primary endpoint was biochemical relapse according to the modified 1997-American Society for Therapeutic Radiology and Oncology and Phoenix definitions. Toxicity was graded using the Radiation Therapy Oncology Group 1991 criteria and the late effects on normal tissues-subjective, objective, management, analytic scales (LENT-SOMA) scales. The patients' quality of life was scored using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item cancer-specific and 25-item prostate-specific modules. Results: The median follow-up was 61 months. According to the 1997-American Society for Therapeutic Radiology and Oncology definition, the 5-year biochemical relapse rate was 39% and 28% in the 70- and 80-Gy arms, respectively (p = .036). Using the Phoenix definition, the 5-year biochemical relapse rate was 32% and 23.5%, respectively (p = .09). The subgroup analysis showed a better biochemical outcome for the higher dose group with an initial prostate-specific antigen level >15 ng/mL. At the last follow-up date, 26 patients had died, 10 of their disease and none of toxicity, with no differences
More>>
Beckendorf, Veronique;
[1]
Guerif, Stephane;
[2]
Le Prise, Elisabeth;
[3]
Cosset, Jean-Marc;
[4]
Bougnoux, Agnes;
[5]
Chauvet, Bruno;
[6]
Salem, Naji;
[7]
Chapet, Olivier;
[8]
Bourdain, Sylvain;
[9]
Bachaud, Jean-Marc;
[10]
Maingon, Philippe;
[11]
Hannoun-Levi, Jean-Michel;
[12]
Malissard, Luc;
[13]
Simon, Jean-Marc;
[14]
Pommier, Pascal;
[15]
Hay, Men;
[16]
Dubray, Bernard;
[17]
Lagrange, Jean-Leon;
[18]
Luporsi, Elisabeth;
[1]
Bey, Pierre
[4]
- Centre Alexis Vautrin, Vandoeuvre les Nancy (France)
- Centre Hospitalier Universitaire, Poitiers (France)
- Centre Eugene Marquis, Rennes (France)
- Institut Curie, Paris (France)
- Hopital Bretonneau Tours (France)
- Institut Sainte-Catherine, Avignon (France)
- Institut Paoli-Calmette, Marseille (France)
- Centre Hospitalier Lyon-Sud, Pierre-Benite (France)
- Centre Rene Gauducheau, Saint Herblain (France)
- Centre Claudius Regaud, Toulouse (France)
- Centre George-Francois Leclerc, Dijon (France)
- Centre Antoine Lacassagne, Nice (France)
- La Chaussee Saint Victor (France)
- Hopital de la Pitie-Salpetriere, Paris (France)
- Centre Leon Berard, Lyon (France)
- Centre Val D'Aurelle, Montpellier (France)
- Centre Henri Becquerel, Rouen (France)
- Hopital Henri-Mondor, Creteil (France)
Citation Formats
Beckendorf, Veronique, Guerif, Stephane, Le Prise, Elisabeth, Cosset, Jean-Marc, Bougnoux, Agnes, Chauvet, Bruno, Salem, Naji, Chapet, Olivier, Bourdain, Sylvain, Bachaud, Jean-Marc, Maingon, Philippe, Hannoun-Levi, Jean-Michel, Malissard, Luc, Simon, Jean-Marc, Pommier, Pascal, Hay, Men, Dubray, Bernard, Lagrange, Jean-Leon, Luporsi, Elisabeth, and Bey, Pierre.
70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial;Prostate cancer; Dose escalation; Conformal radiotherapy; Randomized trial.
United States: N. p.,
2011.
Web.
doi:10.1016/j.ijrobp.2010.03.049.
Beckendorf, Veronique, Guerif, Stephane, Le Prise, Elisabeth, Cosset, Jean-Marc, Bougnoux, Agnes, Chauvet, Bruno, Salem, Naji, Chapet, Olivier, Bourdain, Sylvain, Bachaud, Jean-Marc, Maingon, Philippe, Hannoun-Levi, Jean-Michel, Malissard, Luc, Simon, Jean-Marc, Pommier, Pascal, Hay, Men, Dubray, Bernard, Lagrange, Jean-Leon, Luporsi, Elisabeth, & Bey, Pierre.
70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial;Prostate cancer; Dose escalation; Conformal radiotherapy; Randomized trial.
United States.
https://doi.org/10.1016/j.ijrobp.2010.03.049
Beckendorf, Veronique, Guerif, Stephane, Le Prise, Elisabeth, Cosset, Jean-Marc, Bougnoux, Agnes, Chauvet, Bruno, Salem, Naji, Chapet, Olivier, Bourdain, Sylvain, Bachaud, Jean-Marc, Maingon, Philippe, Hannoun-Levi, Jean-Michel, Malissard, Luc, Simon, Jean-Marc, Pommier, Pascal, Hay, Men, Dubray, Bernard, Lagrange, Jean-Leon, Luporsi, Elisabeth, and Bey, Pierre.
2011.
"70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial;Prostate cancer; Dose escalation; Conformal radiotherapy; Randomized trial."
United States.
https://doi.org/10.1016/j.ijrobp.2010.03.049.
@misc{etde_21587628,
title = {70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial;Prostate cancer; Dose escalation; Conformal radiotherapy; Randomized trial}
author = {Beckendorf, Veronique, Guerif, Stephane, Le Prise, Elisabeth, Cosset, Jean-Marc, Bougnoux, Agnes, Chauvet, Bruno, Salem, Naji, Chapet, Olivier, Bourdain, Sylvain, Bachaud, Jean-Marc, Maingon, Philippe, Hannoun-Levi, Jean-Michel, Malissard, Luc, Simon, Jean-Marc, Pommier, Pascal, Hay, Men, Dubray, Bernard, Lagrange, Jean-Leon, Luporsi, Elisabeth, and Bey, Pierre}
abstractNote = {Purpose: To perform a randomized trial comparing 70 and 80 Gy radiotherapy for prostate cancer. Patients and Methods: A total of 306 patients with localized prostate cancer were randomized. No androgen deprivation was allowed. The primary endpoint was biochemical relapse according to the modified 1997-American Society for Therapeutic Radiology and Oncology and Phoenix definitions. Toxicity was graded using the Radiation Therapy Oncology Group 1991 criteria and the late effects on normal tissues-subjective, objective, management, analytic scales (LENT-SOMA) scales. The patients' quality of life was scored using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item cancer-specific and 25-item prostate-specific modules. Results: The median follow-up was 61 months. According to the 1997-American Society for Therapeutic Radiology and Oncology definition, the 5-year biochemical relapse rate was 39% and 28% in the 70- and 80-Gy arms, respectively (p = .036). Using the Phoenix definition, the 5-year biochemical relapse rate was 32% and 23.5%, respectively (p = .09). The subgroup analysis showed a better biochemical outcome for the higher dose group with an initial prostate-specific antigen level >15 ng/mL. At the last follow-up date, 26 patients had died, 10 of their disease and none of toxicity, with no differences between the two arms. According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively. The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046). Similar results were observed using the LENT-SOMA scale. Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039). The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms. Conclusion: High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.}
doi = {10.1016/j.ijrobp.2010.03.049}
journal = []
issue = {4}
volume = {80}
place = {United States}
year = {2011}
month = {Jul}
}
title = {70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial;Prostate cancer; Dose escalation; Conformal radiotherapy; Randomized trial}
author = {Beckendorf, Veronique, Guerif, Stephane, Le Prise, Elisabeth, Cosset, Jean-Marc, Bougnoux, Agnes, Chauvet, Bruno, Salem, Naji, Chapet, Olivier, Bourdain, Sylvain, Bachaud, Jean-Marc, Maingon, Philippe, Hannoun-Levi, Jean-Michel, Malissard, Luc, Simon, Jean-Marc, Pommier, Pascal, Hay, Men, Dubray, Bernard, Lagrange, Jean-Leon, Luporsi, Elisabeth, and Bey, Pierre}
abstractNote = {Purpose: To perform a randomized trial comparing 70 and 80 Gy radiotherapy for prostate cancer. Patients and Methods: A total of 306 patients with localized prostate cancer were randomized. No androgen deprivation was allowed. The primary endpoint was biochemical relapse according to the modified 1997-American Society for Therapeutic Radiology and Oncology and Phoenix definitions. Toxicity was graded using the Radiation Therapy Oncology Group 1991 criteria and the late effects on normal tissues-subjective, objective, management, analytic scales (LENT-SOMA) scales. The patients' quality of life was scored using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item cancer-specific and 25-item prostate-specific modules. Results: The median follow-up was 61 months. According to the 1997-American Society for Therapeutic Radiology and Oncology definition, the 5-year biochemical relapse rate was 39% and 28% in the 70- and 80-Gy arms, respectively (p = .036). Using the Phoenix definition, the 5-year biochemical relapse rate was 32% and 23.5%, respectively (p = .09). The subgroup analysis showed a better biochemical outcome for the higher dose group with an initial prostate-specific antigen level >15 ng/mL. At the last follow-up date, 26 patients had died, 10 of their disease and none of toxicity, with no differences between the two arms. According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively. The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046). Similar results were observed using the LENT-SOMA scale. Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039). The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms. Conclusion: High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.}
doi = {10.1016/j.ijrobp.2010.03.049}
journal = []
issue = {4}
volume = {80}
place = {United States}
year = {2011}
month = {Jul}
}